Members Login

  • Algorithms
  • Member Directory
  • Order Sets
  • PBMP Business Plans

News & Events

Annual Meeting 2018

"Bridging the World Through Patient Blood Management Partnerships".

Patient Blood Management is at the heart of what we do! SABM delivers the science of PBM as we advance our mission to improve health, increase safety, and reduce healthcare costs through the promotion of knowledge and practice in Patient Blood Management. The SABM 2018 Annual Meeting will feature the following Highlights:

Wednesday, All Day

SABM PBM Certificate Course with Exam

SABM is excited to present what is the first comprehensive Patient Blood Management Certificate Course! This course has been developed by very dedicated and passionate SABM members who are recognized experts in the field of PBM. The course will be offered at the SABM annual meeting and will be of great value to any PBM nurse, PBM coordinator/director, Bloodless Medicine Coordinator, TSO’s, physician PBM medical Director, PBM champions, and advocates. You won’t want to miss this opportunity to be among those who earn the SABM PBM Certificate! What you will learn in one day!

  • Leadership, Teamwork and Change Management
  • Law, Ethics and Patient Rights
  • Physiology of Anemia and Oxygen Delivery
  • Pre-op Evaluation and Preparation of the Surgical Patient
  • Peri-operative PBM
  • The Clotting Cascade
  • Blood Administration and Transfusion Safety
  • Data Collection for Evaluation of Transfusion Practice
  • Profound Anemia when Blood is not an Option

Thursday Morning

Patient Blood Management Program Implementation Bonus Session

Thursday Afternoon

PBM Industry Workshops

Friday Morning – General International Session

Patient Blood Management Challenges and Successes from Global Perspectives

Reports from PBM organizations around the world!

The Approach to PBM in Resource-Poor Regions

Keynote Address: "Blood on Their Hands"– by co-author Donna Shaw

The dramatic exposé of how idealistic attorneys and their heroic, mortally-ill HIV clients

fought to achieve justice and prevent further infections.

Friday Afternoon – PBM Workshops

Management of anemia

Management of coagulation and bleeding in surgical patients

Strengthening of PBM Programs using quality, safety and financial metrics

Best Posters Session

Saturday – General Session

Anemia Management in Cardiac Surgery

PBM in High-Risk Obstetrics

Blood Conservation Strategies in Pediatrics and Cardiac Surgery

PBM Research: Top Ten PBM Articles of the Year

SABM Annual Meeting Registration, PBM Certificate Course REGISTRATION and HOTEL ACCOMMODATION information coming soon!

KUAH to build 'minimal transfusion surgical hospital'

Korea University Anam Hospital (KUAH) said it would become the nation’s first to build a “minimal transfusion surgical hospital” that adopts the Patient Blood Management (PBM) system. There are "transfusion-free" hospitals, but no hospital has a PBM system in Korea.

KUAH plans to set up a task force for the construction of the minimal transfusion surgical hospital in March and discuss how to adopt PBM for six months.

Park Jong-hoon, president of the KUAH, is leading the hospital’s PBM push. Taking office on Jan. 1, Park said he would “make the safest hospital in Korea.” PBM is one of the tools to achieve his goal, he said.

Since Park worked as a professor at the Orthopedics Department, he has been claiming that surgeons should minimize blood transfusion. His argument had nothing to do with any religion. He came to believe in minimal transfusion from his experience and knowledge in advanced countries where hospitals made an effort to minimize blood transfusion. He also learned from clinical evidence that minimal transfusion led to better patient outcomes.

"Six years ago, a vice president of a Swiss pharmaceutical company, which developed high-dose iron injections, came to me and asked why he couldn’t sell high-dose iron injections in Korea. He asked me why Korea did not make efforts to minimize blood transfusion," Park said. "At that time, I couldn’t understand his words. But after I studied in Switzerland for two years, I got to learn what he meant."

From 2015 to 2017, Park worked as the hospital’s medical planning chief. He applied a blood management program to clinical care, asking medical staffs to record the reasons for prescribing blood transfusion and indications. However, he could not force all of the doctors to use the program and only several departments, including Orthopedics, did so.

The limited use of the blood management program made Park aspire to become the hospital’s president. If he becomes the leader, he could push for the hospital’s adoption of PBM, he thought. Immediately after his inauguration on Jan. 15, Park began persuading doctors at the hospital for the PBM adoption.

On Jan. 19, Park made a presentation about the PBM in front of surgeons, anesthesiologists, diagnostic medical specialists, and nurses, at the Yookwangsa Hall, College of Medicine at Korea University. Park explained what kind of efforts hospitals have been making to minimize blood transfusion in advanced nations such as the U.S. and Australia since 2013.

"There is a study that showed simply reminding doctors of the guideline to transfuse blood when the hemoglobin level is less than 7 g/㎗ reduced the amount of blood transfusion by 24 percent," Park said. "In the U.S., doctors discovered that excessive blood sampling was one of the reasons for the drop in hemoglobin levels in patients admitted to the intensive care unit. So, they are now trying to minimize it."

Before he learned about PBM, he used to give 6.9 pints of blood to a surgical patient on average. But after applying PBM in 2013, the amount of blood use went down to 0.15 pint per patient, he noted.

"To correct the patient’s anemia, I used iron shots. During operation, I used Cell Saver, a self-transfusion device. This is how I minimized blood transfusion," Park said.

Park said the minimal transfusion surgical hospital under PBM would enhance KUAH’s competitiveness. It will benchmark Englewood Hospital in New Jersey in the U.S., he said.

"On its homepage, Englewood Hospital says it offers minimally invasive surgery and transfusion-free surgery. The Johns Hopkins Hospital was also PBM-certified by the Joint Commission and the American Association of Blood Banks (AABB)," Park said. "Just like Englewood Hospital, we have to make a minimal transfusion surgical hospital to become more competitive. I want to turn our hospital into Asia’s best one in PBM."

For a start, the hospital will establish a task force in March to prepare for the construction of a minimal transfusion surgical hospital and discuss the matter for six months, Park said.

"We can’t force surgeons to use PBM from the beginning. I will let only those who want it to use the system voluntarily. Our goal is to minimize transfusion and use blood appropriately, not to ban transfusion," he added.

Awareness - NY1 "Week in Review" Show

Click here to view video



At Twin Cities Hospitals, Doing More With Less Blood

Click here to read article



Anemia therapy under recall over hypersensitivity, one death.

The Wall Street Journal (5/22, Jones, Subscription Publication, 2.29M) reports Amag Pharmaceuticals Inc. announced that its marketing partner, Osaka, Japan-based Takeda Pharmaceutical Company, issued a recall for its iron-deficiency treatment Rienso (ferumoxytol), based on the receipt of four reports of hypersensitivity occurring after the drug was administered to patients, one who subsequently died. Although Takeda distributes the anemia treatment in US, Canada and the EU, the recall is limited to a specific lot that was sold in Switzerland, Amag said, adding that the two pharmaceutical firms are reviewing the specific batch of the therapy under recall to determine what might have caused the adverse reactions.

According to Reuters (5/22, Ail), Amag announced the recalled batch of Rienso, which is marketed under the brand name Feraheme in the US and Canada, in an SEC filing yesterday. The Lexington, Massachusetts-based drug maker said it intends to seek approval from Switzerland's regulatory body, Swissmedic, to produce new batches of the therapy to replace the recalled product. Reuters adds that last August, Swissmedic approved Rienso as treatment for iron deficiency anemia in chronic kidney disease patients undergoing dialysis, and the company was hoping to get an extended approval for Rienso to treat anemia in all patients.

Click here to read article



CSL Behring Receives FDA Approval of Kcentra™ for Urgent Warfarin Reversal in Patients with Acute Major Bleeding


CSL Behring announced today that the U.S. Food and Drug Administration (FDA) approved Kcentra™ (Prothrombin Complex Concentrate [Human]), the first non-activated 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy in adult patients with acute major bleeding. The pivotal clinical trial showed that Kcentra met all efficacy and safety endpoints, including the endpoints of hemostatic efficacy and International Normalized Ratio (INR) reduction compared with plasma, the most widely used agent for warfarin reversal in the United States.

Download the press release here



Administrative and Clinical Standards for Patient Blood Management Programs


These Standards provide a framework of those elements SABM feels are essential to development and maintenance of a high-quality Patient Blood Management Program. See Publications in our Resource Center for more information.

Download to review the Fourth Edition Draft of Administrative and Clinical Standards For Patient Blood Management Programs

Administrative and Clinical Standards for Patient Blood Management are copyrighted.



primum non nocere | first do no harm

Considered by many to be the ultimate expression of community participation in healthcare, voluntary blood donation has enabled medicine to make use of this unique and complex liquid organ. Hailed as a life-saving measure since WWII, blood transfusion is one of the most common medical interventions performed worldwide. Nonetheless, emerging scientific evidence is pointing to it being a questionable therapy of unproven benefit.

Amazingly, blood products have escaped the rigors of testing that would measure their safety and efficacy. Furthermore, the gap between science and medical practice is alarming, but not unprecedented. Like in other areas of human endeavor, old habits die hard. The Semmelweis reflex—the knee-jerk rejection of new knowledge that contradicts strong-held beliefs and entrenched norms—helps explain this divide.

Primum non Nocere – First, Do No Harm—examines this concept in the setting of global transfusion practice, and reveals the costly efforts to reduce patient exposure to infectious complications. The film discovers the heartening results achieved by surgeons and blood bankers alike who are guided by this immutable oath, thus bridging the gap between science and widespread belief.

President Bill Clinton and SABM President Aryeh Shander

PBM: A hot topic at the Patient Safety Summit

The Inaugural Patient Safety Science and Technology Summit held in Laguna Niguel California on January 13 and 14, 2013 was a success.  Joe Kiani, President and CEO of Masimo hosted the meeting which was attended by international healthcare leaders. President Bill Clinton gave the keynote address.

 SABM’s President, Aryeh Shander, MD was the moderator of Challenge #3: Overuse of red cell transfusions.  Seven physicians joined Dr Shander in the panel discussion as well as the break out session on red cell overuse: Wael Nabil Fahmey Awada, MD, Keith J. Ruskin, MD, David C. Classen, MD, Howard Shapiro, MD, Charles R. Denham, MD, L.T. Goodnough, MD and John A. Ulatowski, MD.  Of the three challenges, red cell overuse was undoubtedly the least recognized by most attendees.  This was great opportunity for many health care leaders from all over the world to become informed about PBM. 

To see videos from this important summit click the link below.

Red cell Overuse Panel Discussion video:!